All In Biotech

Drug Trial Radar · NCT05954624

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

A Open-Label, Two-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Jul 10, 2023

Primary completion

Nov 20, 2023

Study completion Nov 30, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The drug-drug interaction study had been designed to investigate the effect of ZSP1273 on the pharmacokinetics of digoxin, Rosuvastatin and the effect of Itraconazole and Probenecid on the pharmacokinetics of ZSP1273

Conditions

  • Drug Drug Interaction

Interventions

  • DigoxinDrug

    oral

  • RosuvastatinDrug

    oral

  • ZSP1273Drug

    oral

  • ItraconazoleDrug

    oral

  • ProbenecidDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic - CmaxTime frame: 0-168 hours
  2. Pharmacokinetic -Area under the curve(AUC)Time frame: 0-168 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou University of Chinese medicine

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.